4.6 Review

Metabolic profile in patients with narcolepsy: a systematic review and meta-analysis

Journal

SLEEP MEDICINE
Volume 81, Issue -, Pages 268-284

Publisher

ELSEVIER
DOI: 10.1016/j.sleep.2021.02.040

Keywords

BMI; Diabetes; Dyslipidemia; Hypertension; Metabolic; Narcolepsy

Ask authors/readers for more resources

Narcolepsy patients show metabolic abnormalities, including higher prevalence of obesity, diabetes, hypertension, and dyslipidemia. Additionally, they have higher BMI, waist circumference, and plasma insulin levels compared to non-narcoleptic controls.
Narcolepsy, a sleep disorder characterized by loss of hypocretin neurons, has been associated with metabolic disturbances. Although the metabolic alterations in narcolepsy patients are widely investigated in the literature, the results are controversial. We performed a systematic search of literature to identify metabolic profiling studies in narcolepsy patients. A total of 48 studies were included in the meta-analysis. Narcolepsy patients exhibited higher prevalence of obesity (log OR = 0.93 [0.73-1.13], P < 0.001), diabetes mellitus (log OR = 0.64 [0.34, 0.94], P < 0.001), hypertension (log OR = 0.33 [0.11, 0.55], P < 0.001), and dyslipidemia (log OR = 1.19 [0.60, 1.77], P < 0.001) compared with non-narcoleptic controls. Narcolepsy was associated with higher BMI (SMD = 0.50 [0.32-0.68], P < 0.001), waist circumference (MD = 8.61 [2.03-15.19], P = 0.01), and plasma insulin (SMD = 0.61 [0.14-1.09], P = 0.01). Levels of fasting blood glucose (SMD = -0.25 [ -0.61,0.10], P = 0.15), BMR-RMR (SMD = -0.17 [ -0.52-0.18], P = 0.34), systolic blood pressure (SMD = 0.29 [ -0.39-0.97], P = 0.40), diastolic blood pressure (SMD = 0.39 [ -0.62, 1.40], P = 0.45), CSF melanin-concentrating hormone (MD = 5.56 [ -30.79-41.91], P = 0.76), serum growth hormone (SMD = 7.84 [ -7.90-23.57], P = 0.33), as well as plasma and CSF leptin (SMD = 0.10 [ -1.32-1.51], P = 0.89 and MD = 0.01 [ -0.02-0.04], P = 0.56, respectively) did not significantly differ between narcolepsy patients and controls. These findings necessitate early screening of metabolic alterations and cardiovascular risk factors in narcolepsy patients to reduce the morbidity and mortality rates. (C) 2021 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available